Primary central nervous system lymphoma: Inter‐compartmental progression

Vishal Raval; Elaine Binkley; Mary E. Aronow; Juan Valenzuela; David M. Peereboom; Wei Wei; Sunil Srivastava; Jaqueline Davanzo; Herbert Culver Boldt; Mark P. McGarrey; George N. Papaliodis; Lucia Sobrin; Ivana K. Kim; Dimitrios G. Vavvas; Dean Eliott; Lakshmi Nayak; Emilio Dodds; Francisco Marco del Pont; Arun D. Singh

doi:10.1002/jha2.303

Back

Primary central nervous system lymphoma: Inter‐compartmental progression

Journal article

Open access

Peer reviewed

Primary central nervous system lymphoma: Inter‐compartmental progression

Vishal Raval, Elaine Binkley, Mary E. Aronow, Juan Valenzuela, David M. Peereboom, Wei Wei, Sunil Srivastava, Jaqueline Davanzo, Herbert Culver Boldt, Mark P. McGarrey, …

EJHaem, Vol.3(2), pp.362-370

05/2022

DOI: 10.1002/jha2.303

PMCID: PMC9175875

PMID: 35846050

Files and links (1)

url

https://doi.org/10.1002/jha2.303View

Published (Version of record) Open Access

Abstract

There is limited understanding of the inter‐compartmental progression and treatment outcomes of primary central nervous system lymphoma (PCNSL). In this multicenter retrospective cohort study on 234 patients with PCNSL (median age: 62.5 years [18–92]; median follow‐up 35 months [0.1–237.0]) from 2000 till 2018 were divided into group 1 (ocular, 44 patients): 1A and 1B without and with CNS progression and group 2 (CNS, 190 patients): 2A and 2B without and with ocular progression, respectively. In group 1 (44 patients), 33 patients received local treatment, and 11 patients received systemic treatment. In group 2 (15 patients), six patients received combination treatment, while seven patients received only systemic treatment. A complete response was observed in 19 (43%) and 91 (48%) patients in groups 1 and 2, respectively. The 2‐year progression‐free survival (PFS) was 35% (95% CI: 0.23, 0.54) and 56% (95% CI: 0.49, 0.63) for groups 1 and 2, respectively (p < 0.0001). Age < 60 years was significantly associated with longer PFS (median PFS 48 vs. 24 months, p = 0.01). The overall survival (OS) at 2‐year was similar among groups 1 and 2 (83% and 67%), respectively (p = 0.06). Thus, Initial compartment of involvement does not influence local response rate or OS.

inter‐compartment

primary central nervous system lymphoma

primary central nervous system lymphoma‐ocular variant

primary vitreoretinal lymphoma

progression

treatment

Details

Title: Subtitle: Primary central nervous system lymphoma: Inter‐compartmental progression
Creators: Vishal Raval - Cleveland Clinic
Elaine Binkley - University of Iowa
Mary E. Aronow - Harvard Medical School
Juan Valenzuela - Department of Retina and Ophthalmic Oncology Consultores Oftalmológicos Buenos Aires Argentina
David M. Peereboom - Cleveland Clinic
Wei Wei - Cleveland Clinic
Sunil Srivastava - Cleveland Clinic
Jaqueline Davanzo - Cleveland Clinic
Herbert Culver Boldt - University of Iowa
Mark P. McGarrey - Harvard Medical School
George N. Papaliodis - Harvard Medical School
Lucia Sobrin - Harvard Medical School
Ivana K. Kim - Harvard Medical School
Dimitrios G. Vavvas - Harvard Medical School
Dean Eliott - Harvard Medical School
Lakshmi Nayak - Dana-Farber Cancer Institute
Emilio Dodds - Department of Retina and Ophthalmic Oncology Consultores Oftalmológicos Buenos Aires Argentina
Francisco Marco del Pont - Fleni
Arun D. Singh - Cleveland Clinic
Resource Type: Journal article
Publication Details: EJHaem, Vol.3(2), pp.362-370
DOI: 10.1002/jha2.303
PMID: 35846050
PMCID: PMC9175875
NLM abbreviation: EJHaem
ISSN: 2688-6146
eISSN: 2688-6146
Number of pages: 9
Language: English
Date published: 05/2022
Academic Unit: Ophthalmology and Visual Sciences
Record Identifier: 9984259097102771

Metrics

6 Record Views